Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 444-449

  Sniderman, Allan D ^a   Islam, Shofique ^b   Yusuf, Salim ^b   McQueen, Matthew J ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

ApoB; Cardiovascular risk; Discordance; Non HDL C

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ACCURACY; ACUTE HEART INFARCTION; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ETHNIC GROUP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; REPRODUCIBILITY;

AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS;

EID: 84869503037     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.039     Document Type: Article

References (20)

1. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
2. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
3. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(Suppl. 1):1-44.
4. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
5. Danesh J., Di Angelantonio E., et al. Lipid related markers and cardiovascular risk prediction. JAMA 2012, 307:2499-2506. Emerging Risk Factors Collaboration.
6. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of LDL-C, non-HDL-C and apoB as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
7. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007, 1:583-592.
8. Otvos J.D., Mora S., Shalaurova I., et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011, 5:105-113.
9. Sniderman A.D., St-Pierre A., Cantin B., et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003, 91:1173-1177.
10. Glasziou P., Irwig L., Deeks J.J. When should a new test become the current reference standard?. Ann Intern Med 2008, 148:816-821.
11. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
12. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012, 307:1302-1309.
13. Parish S., Offer A., Clarke R., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125:2469-2478.
14. Sniderman A.D., Williams K., McQueen M.J., et al. When is equal not equal?. J Clin Lipidol 2010, 4:83-88.
15. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Apolipoprotein-B, low-density lipoprotein cholesterol, and long-term risk of coronary heart disease in men. Am J Cardiol 2006, 97:997-1001.
16. Sawar N., Sandhu M.S., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
17. Nordestgaard B.G., Benn M., Schnohr P., et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
18. Sniderman A.D., McQueen M., Contois J., et al. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. J Clin Lipidol 2010, 4:152-155.
19. Sniderman A.D., Tremblay A., Bergeron J., et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol 2007, 1:256-263.
20. Sniderman A.D., Couture P., de Graaf J. Diagnosis and treatment of the apoB dyslipoproteinemias. Nat Clin Endocrinol Metab 2010, 6:335-346.